SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalIncyte (INCY)


Previous 10 Next 10 
To: tuck who wrote (3166)4/9/2018 10:55:00 AM
From: Miljenko Zuanic
   of 3202
 
Indeed, strong data for JAK1 Upadacitinib. Competition for GLPG/GILD too. Two Qs, are Humira response numbers bit on low side and why MACE/Death is pronounced in Humira/placebo? Bit biased in randomization, baseline unbalance?

OT: Nice move in QURE, too!

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tuck who wrote (3166)4/9/2018 2:09:26 PM
From: scaram(o)uche
   of 3202
 
RA.... I still do not understand the fast turnaround from the baricitinib CRL. Guess all will be clear on the 23rd.

Share RecommendKeepReplyMark as Last Read


To: Miljenko Zuanic who wrote (3167)4/9/2018 3:32:04 PM
From: scaram(o)uche
   of 3202
 
OT

>> OT: Nice move in QURE, too! <<

Look at the daily chart for qure and once versus that for sgmo. Edit et al. having trouble due to fear over pre-existing antibody?

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: scaram(o)uche who wrote (3169)4/9/2018 8:31:22 PM
From: Miljenko Zuanic
   of 3202
 
Seems that AAV5 ( AMT-061) has lower pre-existing mAbs titar! They are going strait with dose of 2 x 10^13 gc/kg: clinicaltrials.gov

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (3170)4/10/2018 2:02:14 PM
From: scaram(o)uche
   of 3202
 
Ah, OK. Thought the big move was all avxs sentiment. Thanks!

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: scaram(o)uche who wrote (3171)4/10/2018 2:12:31 PM
From: Miljenko Zuanic
   of 3202
 
OT: ONCE benefited the most! EOM

Share RecommendKeepReplyMark as Last Read


To: tuck who wrote (3123)4/23/2018 5:03:16 PM
From: tuck
   of 3202
 
Now the FDA AdCom vote. Two doses. 10-5 in favor of 2mg, and 10-5 against the 4mg on the risk-benefit metric. If approved, can the 2 mg dose make commercial inroads on competing products from PFE and ABBV?

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tuck who wrote (3173)4/23/2018 5:50:35 PM
From: Miljenko Zuanic
1 Recommendation   of 3202
 
Never hear so much (and so many) incompetent panels of RA "experts"!

They do not know what they voted and for what they voted?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (3174)4/24/2018 11:18:53 AM
From: scaram(o)uche
   of 3202
 
Therapeutic window!! Large enough that a panel of FDA-deemed experts said yes!

;-(

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: scaram(o)uche who wrote (3175)4/24/2018 11:56:50 AM
From: Miljenko Zuanic
   of 3202
 
Not clear is it JAK2 related, not related to platelets count (which actually decrease, not increase), so search for an answer not condemn drug in start. No trial can be executed to CONFIRM safety signal (not ETHICAL). So, THE ONLY WAY is REAL LIFE EXPERIENCE (controlled with BOX warning and proper management). Hope NEW FDA will be more open for suggestions!!??

Approval without option to increase dose, IF needed, is worthless.
Some panel members had open mind, but they were in minority.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10